Fluorophores advanced glycation end products (AGEs)-to-NADH ratio is predictor for diabetic chronic kidney and cardiovascular disease

J Diabetes Complications. 2015 Sep-Oct;29(7):893-7. doi: 10.1016/j.jdiacomp.2015.06.006. Epub 2015 Jun 16.

Abstract

Aims: An imbalance in advanced glycation end products (AGEs) and NADH formation has been associated with diabetic chronic kidney disease (CKD) and cardiovascular disease (CVD). No data have been reported on simultaneous measurement of AGEs and NADH in type 2 diabetes (T2DM) patients. We aimed to compare AGEs, NADH and the AGEs-to-NADH ratio in T2DM and controls, and to assess its relationship with diabetic CKD and CVD.

Material and methods: In this cross-sectional study, we measured serum AGEs (370/435nm) and NADH (370/460nm) in T2DM patients (n=63) and controls (n=25) using fluorescence spectroscopy. The AGEs-to-NADH ratio was analyzed according to diabetic CKD and CVD.

Results: We found significantly higher AGEs-to-NADH ratio in T2DM compared to controls. The AGEs-to-NADH ratio was significantly associated with triglycerides, blood glucose, HDL-cholesterol, estimated glomerular filtration rate. The AGEs-to-NADH ratio was a significant predictor for the presence of diabetic CKD and CVD when using ROC curves. Multivariate analysis showed that triglycerides and the presence of T2DM were predictors for the AGEs-to-NADH ratio.

Conclusions: These findings suggest that the fluorophores AGEs-to-NADH ratio could be a new biomarker for the presence of diabetic CKD and CVD.

Keywords: Advanced glycation end products; Cardiovascular disease; Chronic kidney disease; Fluorescence spectroscopy; NADH; Type 2 diabetes mellitus.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood
  • Cardiovascular Diseases / blood*
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / physiopathology
  • Cohort Studies
  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / complications
  • Diabetic Nephropathies / blood*
  • Diabetic Nephropathies / epidemiology
  • Diabetic Nephropathies / physiopathology
  • Disease Progression
  • Female
  • Glycation End Products, Advanced / blood*
  • Humans
  • Linear Models
  • Male
  • Microscopy, Fluorescence / methods
  • Middle Aged
  • Multivariate Analysis
  • NAD / blood*
  • Predictive Value of Tests
  • Prognosis
  • ROC Curve
  • Renal Insufficiency, Chronic / blood
  • Renal Insufficiency, Chronic / epidemiology
  • Renal Insufficiency, Chronic / physiopathology
  • Risk Assessment

Substances

  • Biomarkers
  • Glycation End Products, Advanced
  • NAD